Regulatory challenges and global trade implications of genome editing in agriculture.

IF 4.8 3区工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Frontiers in Bioengineering and Biotechnology Pub Date : 2025-06-19 eCollection Date: 2025-01-01 DOI:10.3389/fbioe.2025.1609110

Danilo Fernández Ríos, Silverio Andrés Quintana, Pilar Gómez Paniagua, Andrea Alejandra Arrúa, Gustavo René Brozón, Moises Santiago Bertoni Hicar, Andrés Castro Alegría, María Florencia Goberna

{"title":"Regulatory challenges and global trade implications of genome editing in agriculture.","authors":"Danilo Fernández Ríos, Silverio Andrés Quintana, Pilar Gómez Paniagua, Andrea Alejandra Arrúa, Gustavo René Brozón, Moises Santiago Bertoni Hicar, Andrés Castro Alegría, María Florencia Goberna","doi":"10.3389/fbioe.2025.1609110","DOIUrl":null,"url":null,"abstract":"<p><p>Genome editing revolutionized agriculture by improving crop productivity, disease resistance, and adaptation to adverse climatic conditions. However, it has faced significant regulatory challenges due to divergent regulations between regions. Although Europe classified these organisms as genetically modified organisms, Africa, Asia, and Latin America implemented more flexible regulatory frameworks, which encouraged innovation and the participation of small companies. These differences could generate high costs, delays in commercialization, and difficulties in product traceability, affecting research and development decisions. This article analyzes the main regulatory challenges and their impact on global trade, proposing strategies for regulatory harmonization to promote transparency, reduce trade barriers, and maximize the potential of these technologies in the face of global challenges such as food security and climate change.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1609110"},"PeriodicalIF":4.8000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222225/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1609110","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Genome editing revolutionized agriculture by improving crop productivity, disease resistance, and adaptation to adverse climatic conditions. However, it has faced significant regulatory challenges due to divergent regulations between regions. Although Europe classified these organisms as genetically modified organisms, Africa, Asia, and Latin America implemented more flexible regulatory frameworks, which encouraged innovation and the participation of small companies. These differences could generate high costs, delays in commercialization, and difficulties in product traceability, affecting research and development decisions. This article analyzes the main regulatory challenges and their impact on global trade, proposing strategies for regulatory harmonization to promote transparency, reduce trade barriers, and maximize the potential of these technologies in the face of global challenges such as food security and climate change.

查看原文本刊更多论文

农业基因组编辑的监管挑战和全球贸易影响。

基因组编辑通过提高作物生产力、抗病能力和对恶劣气候条件的适应能力，彻底改变了农业。然而，由于地区之间的监管差异，它面临着重大的监管挑战。尽管欧洲将这些生物归类为转基因生物，但非洲、亚洲和拉丁美洲实施了更灵活的监管框架，鼓励创新和小企业的参与。这些差异可能产生高成本、商业化延迟和产品可追溯性困难，从而影响研究和开发决策。本文分析了主要的监管挑战及其对全球贸易的影响，提出了监管协调战略，以提高透明度，减少贸易壁垒，并在面临粮食安全和气候变化等全球挑战时最大限度地发挥这些技术的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering

CiteScore

8.30

自引率

5.30%

发文量

2270

审稿时长

12 weeks

期刊介绍： The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.